id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-327575-5pcnuqgy	Morrisette, Taylor	The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse	2020-08-01		.txt	text/plain	5447	233	45	The objective of this review was to describe the current understanding of the PK/PD and dose selection of HCQ against SARS-CoV-2, discuss knowledge gaps, and identify future studies that are needed to optimize the efficacy and safety of treatments against COVID-19. Although studies completed thus far show variable results, Arshad and colleagues performed a large multicenter, retrospective, observational analysis that evaluated patients hospitalized because of a COVID-19-related admission receiving HCQ 400 mg twice daily on day 1, followed by HCQ 200 mg twice daily on days 2 to 5 [14] [15] [16] [17] . Furthermore, the World Health Organization discontinued the HCQ arm in the Solidarity trial because it showed ''little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care'' (HCQ dosed 800 mg twice daily on day 1, followed by HCQ 400 mg twice daily for a total of 10 days), and the Food and Drug Administration revoked the emergency use authorization to utilize HCQ for the treatment of COVID-19 [16] [17] [18] .	./cache/cord-327575-5pcnuqgy.txt	./txt/cord-327575-5pcnuqgy.txt